Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Receivables (2020 - 2025)

Legend Biotech filings provide 6 years of Change in Receivables readings, the most recent being $25.8 million for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 108.67% to $25.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$72000.0, a 125.17% decrease, with the full-year FY2024 number at $93.8 million, up 194.72% from a year prior.
  • Change in Receivables hit $25.8 million in Q3 2025 for Legend Biotech, up from -$26.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $96.7 million in Q1 2024 to a low of -$99.0 million in Q4 2023.
  • Median Change in Receivables over the past 5 years was $34000.0 (2023), compared with a mean of $4.0 million.
  • Biggest five-year swings in Change in Receivables: tumbled 319416.13% in 2023 and later soared 284411.76% in 2024.
  • Legend Biotech's Change in Receivables stood at -$48.9 million in 2021, then skyrocketed by 99.94% to -$31000.0 in 2022, then tumbled by 319416.13% to -$99.0 million in 2023, then skyrocketed by 94.36% to -$5.6 million in 2024, then skyrocketed by 562.02% to $25.8 million in 2025.
  • The last three reported values for Change in Receivables were $25.8 million (Q3 2025), -$26.2 million (Q2 2025), and $5.9 million (Q1 2025) per Business Quant data.